ClinicalTrials.gg
TerminatedNCT01122927ATTAIN 267Updated Feb 8, 2016Results posted

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

A Phase 3 interventional study of Aripiprazole in Adolescent Schizophrenia and Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 101 sites in 13 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-02-08.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
524
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Mania with a site in United States — 5 open to participants now, 5 under way, 4 of them phase 3. Mania · United States.

Enrollment
4th of 88
524 · median 83
Started
2010
with 8 others
Phase 3
32 of 94
4 open now
Registered
68th of 94
by date
Lead sponsor
6 of 94
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 94 studies in Mania with a site in United States, this one is the 4th largest by enrollment of the 88 interventional ones that give a count, is one of 9 that started in 2010, is one of 32 in phase 3, and was the 68th registered.

Mania

167 studies on the registry are indexed under Mania; 14 are open to participants now.

Browse Mania studies →

Open to participants now

5 of the 94 studies in Mania with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Mania with a site in United States, or all of them as a file.
02

Study summary

This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.

The study will enroll new subjects (hereafter referred as "de novo" subjects) with schizophrenia, or bipolar I disorder, manic or mixed episode with or without psychotic features, and rollover subjects with schizophrenia from 31-09-266 (hereafter referred to as "Study 266"). All de novo subjects must enter the screening period of the study. Subjects who are screened and are not required to go through Phase 1 will complete a Phase 2 baseline visit prior to their participation in Phase 2.

Study Design: Treatment, Single Group Assignment, Open Label, Active Control, Safety/Efficacy Study

03

Conditions studied

  • Adolescent Schizophrenia
  • Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

Keywords

  • schizophrenia
  • adolescent
  • bipolar
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects 13-17 years old (Schizophrenia); Subjects 10-17 years old (Bipolar manic or mixed episode)* [*Bulgaria will enroll Schizophrenia subjects only.]
  • Subjects with a current diagnosis of schizophrenia, and a history of the illness (diagnosis or symptoms) for at least 6 months prior to screening (as per subject, family, or healthcare provider, or by previous medical records).
  • Subjects with a current diagnosis of bipolar I disorder, manic or mixed episode with or without psychotic features (diagnosis or symptoms) experiencing symptoms for at least 1 week prior to screening. * [*These subjects will not be eligible to enroll in Bulgaria]
  • Subjects who have shown previous response to antipsychotic treatment (other than clozapine) and are not resistant to treatment with other antipsychotics.
  • Subjects who are currently being treated with oral antipsychotics other than clozapine, and are not resistant to treatment with other antipsychotics.
  • Inpatient or outpatient status, with the exception of acute hospitalization due to psychiatric reasons at the time of screening or before Phase 2.

Exclusion criteria

Exclusion Criteria:

  • All subjects: diagnosis of schizoaffective disorder, autism, pervasive developmental disorder (PDD), OCD, or PTSD.
  • Subjects with schizophrenia: a current major depressive episode.
  • Subjects with bipolar manic or mixed episode: presenting with a clinical picture and/or history that is consistent with a diagnosis of bipolar II disorder or bipolar disorder not otherwise specified.
  • Subjects with delirium, dementia, amnesia or other cognitive disorders; subjects with psychotic symptoms that are better accounted for by another general medical condition(s) or direct effect of a substance (i.e., medication, illicit drug use, etc.).
  • Subjects with any neurological disorder, with the exception of Tourette's syndrome.
  • Subjects experiencing major depressive episode at the time of screening other than subjects diagnosed with bipolar I disorder mixed episode.
  • Subjects who are currently receiving clozapine or have received clozapine at any time in the past are ineligible for entry into the study.
  • Subjects who meet the criteria for substance dependence (including alcohol and benzodiazepines, but excluding caffeine and nicotine) within the past 180 days prior to screening.
  • Subjects who have epilepsy, a history of seizures (except for a single childhood febrile seizure or post-traumatic seizure), or a history of severe head trauma or stroke, or have a history or current evidence of other unstable medical conditions.
  • Subjects with a history of subclinical hypothyroidism (TSH ≥ 4.0 mIU/L), known hypothyroidism, or hyperthyroidism (unless the condition has been stabilized with medications for at least 90 days prior to entry into Phase 1 or Phase 2).
  • Subjects who have a medical history of uncontrolled diabetes, labile or unstable diabetes (brittle diabetes), newly diagnosed diabetes, or abnormal blood glucose levels (defined as fasting blood glucose ≥ 125 mg/dL).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
524 participants (actual)

Study arms

  • Experimental
    Phase 1 and Phase 2

    Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

    Drug: Aripiprazole

Interventions

  • Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant or participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. A treatment emergent adverse event (TEAE) was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study medication, whether or not considered to have a causal relationship with the study medication. A serious-AE or reaction was any untoward occurrence that, at any dose, was fatal, life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was any other medically significant event that, based on appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Adverse events were recorded from the time of the informed consent was signed throughout the 24 month treatment period until the follow-up visit 30 (± 3) days after the end of trial.

Secondary outcomes

  1. Incidence of Laboratory Values of Potential Clinical Relevance

    The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.

    Time frame: Baseline to Month 24

  2. Incidence of Physical Examination Findings of Potential Clinical Relevance

    The physical examination evaluation was one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.

    Time frame: Baseline to Month 24

  3. Incidence of Vital Signs of Potential Clinical Relevance

    Vital signs are taken at Baseline, Weeks 1, 2, 3, 4, 6, 8, and Months 3, 4, 6, 9, 12, 15, 18, 21, 24 of Phase 2 (Visits beyond Month 12 only for de novo subjects). Assessments included orthostatic (supine and standing) blood pressure (BP), heart rate and body temperature. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Abnormal vital signs in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.

    Time frame: Baseline to Month 24

  4. Mean Change From Baseline by Week in Abnormal Involuntary Movement Scale (AIMS)

    The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.

    Time frame: Baseline to Month 24

  5. Mean Change From Baseline by Week in Simpson-Angus Scale (SAS) Total Score

    The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.

    Time frame: Baseline to Month 24

  6. Mean Change From Baseline by Week in Barnes Akathisia Rating Scale (BARS) Score

    The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).

    Time frame: Baseline to Month 24

  7. Number of Participants With Cognitive Impairment for Each New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)

    The NY-AACENT is not a validated scale. It was included in this trial because of concerns that regulatory authorities (the European Committee for Medicinal Products for Human Use \[CHMP\] and the Paediatric Sub-Committee of the European Medicinal Agency \[PDCO\]) had regarding drug induced cognitive impairment. No validated scale addressing these issues was available at the time of the trial. The NY-AACENT was used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems. It was specifically designed to be used in pediatric populations (ages 12 to 17), but could have been utilized with other age groups, as appropriate.

    Time frame: Baseline to Month 24

  8. Baseline and Post-Baseline Tanner Staging

    Tanner staging was completed together with the physical examination by the same trial-affiliated clinician in the most inconspicuous manner for the participant as possible. Tanner staging assessment consisted of 2 domains (pubic hair and breast development) for girls and 3 domains (pubic hair, penis development, and testes development) for boys. A participant who reached Stage 5 (both in pubic hair and genitalia) did not need to continue with Tanner Staging assessment and the Tanner Staging scales of this participant were imputed as 5 for all of the following scheduled time points up to and including the completion visit/ET visit. The clinician arrived at a single score summarizing the domains (not individual domain scores) when evaluating the participant. The total shift data for last visit is presented below.

    Time frame: Baseline to Last Visit

  9. Mean Change From Baseline for Columbia-Suicide Severity Rating Scale (C-SSRS) in Suicidal Ideation Intensity Total Score

    Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.

    Time frame: Baseline to Month 24

  10. Incidence of Suicidality, Suicidal Behavior and Suicidal Ideation

    Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The below reported N value is the number of participants with specified suicidal ideation/behavior at the given time point.

    Time frame: Baseline to Month 24

  11. Percentage of Participants Who Discontinued Due to All Adverse Events

    The percentage of participants who discontinued due to all causes other than sponsor terminating the trial was measured from the date of entering the open-label treatment phase to the date of ET for discontinued participants in the open-label treatment phase (ie, time to discontinuation = date of discontinuation \[or date of completion for completed participants\] - date of participant entering the open-label treatment phase + 1). If the participants completed the trial or were discontinued due to the sponsor terminating the trial, they were censored at the time of completion or trial termination, respectively.

    Time frame: Baseline to Month 24

  12. Mean Change From Baseline in Positive and Negative Symptoms Score (PANSS) Total Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline to Month 24

  13. Mean Change From Baseline in PANSS Positive Subscale Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline to Month 24

  14. Mean Change From Baseline in PANSS Negative Subscale Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline to Month 24

  15. Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline to Month 24

  16. Mean Change in Clinical Global Impression-Improvement (CGI-I) Score

    The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

    Time frame: Baseline to Month 24

  17. Mean Change From Baseline in Young Mania Rating Scale (YMRS) Score

    The YMRS consists of 11 items assessing the core symptoms of mania and was used to assess participants with bipolar I disorder, manic and mixed episodes with or without psychotic features: elevated mood, increased motor activity - energy, sexual interest, sleep, irritability, speech (rate and amount), language - thought disorder, content, disruptive - aggressive behavior, appearance, and insight. Each item had 5 or 9 grades of severity, with lower scores indicating milder symptoms. The number of raters within each trial center was to be kept to a minimum. The YMRS Total Score (range 0 to 44) is the sum of the rating scores for 11 items for assessing the core symptoms of mania. A missing value for any YMRS assessment item(s) could have resulted in a missing YMRS Total Score. A higher YMRS Total Score represents greater severity. In this study, 94 participants had bipolar disorder, this explains the N=94 in the table below and these were de novo participants.

    Time frame: Baseline to Month 24

  18. Mean Change From Baseline in Clinical Global Impression Scale - Bipolar (CGI-BP) Version Severity Score

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Data for 94 de novo participants were available with bipolar disorder.

    Time frame: Baseline to Month 24

  19. Mean Change From Baseline in Clinical Global Impression Scale - Bipolar Version Improvement Score

    The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Only 94 participants had data at Baseline to explain the N=94 in the table below and these were de novo participants.

    Time frame: Baseline to Month 24

  20. Mean Change From Baseline in General Behavior Inventory (GBI) Scale Total Score for Mania and Depression in Both Parent/Guardian and Subject Version of the Scale

    The GBI is a self-report inventory with 73 items focusing on mood-related behaviors, including depressive, hypomanic, and biphasic symptoms. For this trial, two 20-item subscales were utilized: one was completed by the parent/guardian or legal representative, as applicable for local laws, and the other was completed by the participant. Responses were given on a 4-point Likert scale, with 0 being never or hardly ever and 3 being very often or almost constantly. The GBI Total Score for mania (range 0 to 30) is the sum of scores for items 1 to 10 and the GBI Total Score for depression (range 0 to 30) is the sum of scores for items 11 to 20 in the GBI Parent/Guardian or Subject Version panel. Scores from the Parent/Guardian and participant Versions were summarized separately. A missing value for any GBI assessment items could have resulted in a missing GBI Total Score. High scores represent greater psychopathology. Data was only available for 80 de novo participants with bipolar disorder.

    Time frame: Baseline to Month 24

  21. Mean Change From Baseline in the Attention Deficit Hyperactive Disorders Rating (ADHD-RS-IV) Scale Score

    The ADHD-RS-IV is a reliable and easy-to-administer instrument both for diagnosing ADHD in children and adolescents and for assessing treatment response. Containing 18 items, the scale was linked directly to DSM-IV-TR diagnostic criteria for ADHD. There were 3 versions of the scale: a parent questionnaire on home behaviors (English), a parent questionnaire on home behaviors (Spanish), and a teacher questionnaire on classroom behaviors. For this trial, the parent questionnaire on home behaviors (English) was utilized. The ADHD-RS-IV Total Score (range 0 to 54) is the sum of rating scores for 18 items, with higher scores representing greater severity. A missing value for any ADHD-RS-IV assessment items could have resulted in a missing ADHD-RS-IV Total Score. Data were only available for 82 participants with bipolar disorder and these were de novo participants.

    Time frame: Baseline to Month 24

  22. Mean Change From Baseline in Children's Global Assessment Scale (CGAS) in Bipolar (de Novo Participants)

    The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6 to 17. It was adapted from the Adults Global Assessment Scale. The Global Assessment Scale was a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS Score (range 1 to 100) is a single-item score for rating a child's general level of functioning on a health-illness continuum, with higher scores representing better functioning.

    Time frame: Baseline to Month 24

07

Results

Posted Feb 8, 2016
Limitations and caveats
The study was terminated by the Sponsor as the European Medicines Agency P/99/2011Aripiprazole PIP which directed the sponsor to provide 2 years of safety data for at least 100 participants. The objective was met in April 2014.

Participant flow

This trial was conducted in 524 participants at 118 trial sites in the following 13 countries: Bulgaria, Croatia, Hungary, India, Malaysia, Philippines, Poland, Romania, Russia, Serbia, Taiwan, Ukraine, and the United States.

Period 1 - Conversion Phase
Participant flow — Period 1 - Conversion Phase
MilestoneConversion PhaseOpen-label Treatment Phase
Started2970
Completed2830
Not completed140
Withdrew: Adverse event30
Withdrew: Met withdrawal criteria10
Withdrew: Physician decision20
Withdrew: Withdrawal by subject70
Withdrew: Protocol deviation10
Period 2- Open-label Treatment Phase
Participant flow — Period 2- Open-label Treatment Phase
MilestoneConversion PhaseOpen-label Treatment Phase
Started0510
Completed0198
Not completed0312
Withdrew: Lost to follow-up021
Withdrew: Adverse event033
Withdrew: Sponsor discontinued trial0165
Withdrew: Met withdrawal criteria09
Withdrew: Physician decision012
Withdrew: Withdrawal by subject065
Withdrew: Lack of efficacy07

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant or participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. A treatment emergent adverse event (TEAE) was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study medication, whether or not considered to have a causal relationship with the study medication. A serious-AE or reaction was any untoward occurrence that, at any dose, was fatal, life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was any other medically significant event that, based on appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
Adverse events were recorded from the time of the informed consent was signed throughout the 24 month treatment period until the follow-up visit 30 (± 3) days after the end of trial.
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsOpen-label Treatment Phase
Participants with TEAEs349
Participants with serious TEAEs49
Participants with severe TEAEs33
Discontinued due to AEs32
SecondaryIncidence of Laboratory Values of Potential Clinical Relevance

The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.

Time frame:
Baseline to Month 24
Reported as:
Number · participants
Incidence of Laboratory Values of Potential Clinical Relevance
participantsOpen-label Treatment Phase
Chemistry-Alanine transaminase11
Chemistry-Aspartate transaminase8
Chemistry-Bilirubin, total20
Chemistry-Calcium30
Chemistry-Chloride158
Chemistry-Cholesterol, total, fasting68
Chemistry-Creatine phosphokinase, total40
Chemistry-Glutamyl transferase78
Chemistry-HDL cholesterol, fasting128
Chemistry-LDL cholesterol, calculation,2
Chemistry-Phosphorus inorganic135
Chemistry-Protein, total serum81
Chemistry-Triglycerides, fasting46
Hematology-Eosinophils19
Hematology-Hemoglobin14
Hematology-White blood cell count9
Urinalysis-Protein, urine348
Urinalysis-Specific gravity188
Others-Insulin49
Others-Insulin, fasting78
Others-Prolactin324
SecondaryIncidence of Physical Examination Findings of Potential Clinical Relevance

The physical examination evaluation was one of the parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.

Time frame:
Baseline to Month 24
Reported as:
Number · participants
Incidence of Physical Examination Findings of Potential Clinical Relevance
participantsOpen-label Treatment Phase
Incidence of Physical Examination Findings of Potential Clinical Relevance0
SecondaryIncidence of Vital Signs of Potential Clinical Relevance

Vital signs are taken at Baseline, Weeks 1, 2, 3, 4, 6, 8, and Months 3, 4, 6, 9, 12, 15, 18, 21, 24 of Phase 2 (Visits beyond Month 12 only for de novo subjects). Assessments included orthostatic (supine and standing) blood pressure (BP), heart rate and body temperature. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria. Abnormal vital signs in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.

Time frame:
Baseline to Month 24
Reported as:
Number · participants
Incidence of Vital Signs of Potential Clinical Relevance
participantsOpen-label Treatment Phase
Heart rate supine-Increase ≥15 bpm1
Heart rate supine-Decrease ≥15 bpm1
Heart rate standing-Increase ≥15 bpm4
Heart rate standing-Decrease ≥15 bpm0
Systolic supine bp-Increase ≥20 mmHg36
Systolic supine bp-Decrease ≥20 mmHg31
Systolic standing bp-Increase ≥20 mmHg38
Systolic standing bp-Decrease ≥20 mmHg40
Diastolic supine bp-Increase ≥15 mmHg41
Diastolic supine bp-Decrease ≥15 mmHg19
Diastolic standing bp-Increase ≥15 mmHg53
Diastolic standing bp-Decrease ≥15 mmHg13
Weight gain ≥7%195
Weight loss ≥7%45
SecondaryMean Change From Baseline by Week in Abnormal Involuntary Movement Scale (AIMS)

The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline by Week in Abnormal Involuntary Movement Scale (AIMS)
Units on a scaleOpen-label Treatment Phase
Week 1 (N=486)-0.02 ± 0.24
Week 2 (N=507)-0.01 ± 0.25
Week 3 (N=507)0.01 ± 0.36
Week 4 (N=507)-0.01 ± 0.27
Week 6 (N=507)0.02 ± 0.56
Week 8 (N=507)-0.02 ± 0.28
Month 3 (N=507)-0.00 ± 0.31
Month 6 (N=507)-0.02 ± 0.40
Month 9 (N=506)0.01 ± 0.55
Month 12 (N=507)-0.02 ± 0.41
Month 15 (N=360)-0.01 ± 0.43
Month 18 (N=360)-0.04 ± 0.35
Month 21 (N=360)-0.01 ± 0.52
Month 24 (N=360)-0.04 ± 0.34
SecondaryMean Change From Baseline by Week in Simpson-Angus Scale (SAS) Total Score

The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline by Week in Simpson-Angus Scale (SAS) Total Score
Units on a scaleOpen-label Treatment Phase
Week 1 (N=486)-0.08 ± 0.89
Week 2 (N=507)-0.11 ± 1.22
Week 3 (N=507)-0.08 ± 1.23
Week 4 (N=507)-0.18 ± 1.37
Week 6 (N=507)-0.12 ± 1.49
Week 8 (N=507)-0.21 ± 1.34
Month 3 (N=507)-0.23 ± 1.56
Month 6 (N=507)-0.31 ± 1.48
Month 9 (N=506)-0.35 ± 1.50
Month 12 (N=507)-0.36 ± 1.51
Month 15 (N=360)-0.43 ± 1.78
Month 18 (N=360)-0.48 ± 1.74
Month 21 (N=360)-0.49 ± 1.82
Month 24 (N=360)-0.53 ± 1.81
SecondaryMean Change From Baseline by Week in Barnes Akathisia Rating Scale (BARS) Score

The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia).

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline by Week in Barnes Akathisia Rating Scale (BARS) Score
Units on a scaleOpen-label Treatment Phase
Week 1 (N=487)-0.02 ± 0.26
Week 2 (N=507)-0.02 ± 0.35
Week 3 (N=507)-0.02 ± 0.35
Week 4 (N=507)-0.03 ± 0.33
Week 6 (N=507)-0.03 ± 0.36
Week 8 (N=507)-0.02 ± 0.41
Month 3 (N=507)-0.00 ± 0.45
Month 6 (N=507)-0.03 ± 0.44
Month 9 (N=506)-0.04 ± 0.43
Month 12 (N=507)-0.04 ± 0.42
Month 15 (N=360)-0.02 ± 0.47
Month 18 (N=360)-0.05 ± 0.48
Month 21 (N=360)-0.04 ± 0.50
Month 24 (N=360)-0.05 ± 0.47
SecondaryNumber of Participants With Cognitive Impairment for Each New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)

The NY-AACENT is not a validated scale. It was included in this trial because of concerns that regulatory authorities (the European Committee for Medicinal Products for Human Use \[CHMP\] and the Paediatric Sub-Committee of the European Medicinal Agency \[PDCO\]) had regarding drug induced cognitive impairment. No validated scale addressing these issues was available at the time of the trial. The NY-AACENT was used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems. It was specifically designed to be used in pediatric populations (ages 12 to 17), but could have been utilized with other age groups, as appropriate.

Time frame:
Baseline to Month 24
Reported as:
Number · participants
Number of Participants With Cognitive Impairment for Each New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)
participantsOpen-label Treatment Phase
Working memory237
Attention/vigilance306
Verbal learning/memory233
Visual learning/memory138
Reasoning and problem solving308
Speed of processing276
Social congnition307
SecondaryBaseline and Post-Baseline Tanner Staging

Tanner staging was completed together with the physical examination by the same trial-affiliated clinician in the most inconspicuous manner for the participant as possible. Tanner staging assessment consisted of 2 domains (pubic hair and breast development) for girls and 3 domains (pubic hair, penis development, and testes development) for boys. A participant who reached Stage 5 (both in pubic hair and genitalia) did not need to continue with Tanner Staging assessment and the Tanner Staging scales of this participant were imputed as 5 for all of the following scheduled time points up to and including the completion visit/ET visit. The clinician arrived at a single score summarizing the domains (not individual domain scores) when evaluating the participant. The total shift data for last visit is presented below.

Time frame:
Baseline to Last Visit
Reported as:
Number · participants
Baseline and Post-Baseline Tanner Staging
participantsTanner Score at Baseline of 1Tanner Score at Baseline of 2Tanner Score at Baseline of 3Tanner Score at Baseline of 4Tanner Score at Baseline of 5
Last Visit (Post-Baseline score of 1) (N= 1)10000
Last Visit (Post-Baseline score of 2) (N= 9)45000
Last Visit (Post-Baseline score of 3) (N= 39)292800
Last Visit (Post-Baseline score of 4) (N= 134)0733940
Last Visit (Post-Baseline score of 5) (N= 327)0318102204
SecondaryMean Change From Baseline for Columbia-Suicide Severity Rating Scale (C-SSRS) in Suicidal Ideation Intensity Total Score

Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline for Columbia-Suicide Severity Rating Scale (C-SSRS) in Suicidal Ideation Intensity Total Score
Units on a scaleOpen-label Treatment Phase
Week 1 (N= 487)-0.4 ± 2.1
Week 2 (N= 483)-0.4 ± 2.2
Week 3 (N= 477)-0.4 ± 2.2
Week 4 (N= 491)-0.4 ± 2.2
Week 6 (N= 488)-0.3 ± 2.1
Week 8 (N= 484)-0.4 ± 2.0
Month 3 (N= 478)-0.3 ± 2.2
Month 4 (N= 472)-0.3 ± 2.1
Month 6 (N= 458)-0.2 ± 2.5
Month 9 (N= 407)-0.2 ± 1.8
Month 12 (N= 302)-0.3 ± 2.0
Month 15 (N= 261)-0.2 ± 1.9
Month 18 (N= 247)-0.1 ± 2.0
Month 21 (N= 212)-0.1 ± 1.8
Month 24 (N= 180)-0.0 ± 1.9
Last Visit (N= 507)-0.1 ± 2.5
SecondaryIncidence of Suicidality, Suicidal Behavior and Suicidal Ideation

Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The below reported N value is the number of participants with specified suicidal ideation/behavior at the given time point.

Time frame:
Baseline to Month 24
Reported as:
Number · participants
Incidence of Suicidality, Suicidal Behavior and Suicidal Ideation
participantsOpen-label Treatment Phase
Complete suicidality0
Suicidality32
Suicidal behavior5
Emergence of suicidal behavior3
Suicidal ideation31
Emergence of suicidal ideation19
Emergence of serious suicial ideation2
Worsening of suicidal ideation26
SecondaryPercentage of Participants Who Discontinued Due to All Adverse Events

The percentage of participants who discontinued due to all causes other than sponsor terminating the trial was measured from the date of entering the open-label treatment phase to the date of ET for discontinued participants in the open-label treatment phase (ie, time to discontinuation = date of discontinuation \[or date of completion for completed participants\] - date of participant entering the open-label treatment phase + 1). If the participants completed the trial or were discontinued due to the sponsor terminating the trial, they were censored at the time of completion or trial termination, respectively.

Time frame:
Baseline to Month 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Due to All Adverse Events
percentage of participantsOpen-label Treatment Phase
From study NCT01149655 (N= 148)3.4
De Novo (N= 362)7.7
SecondaryMean Change From Baseline in Positive and Negative Symptoms Score (PANSS) Total Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Positive and Negative Symptoms Score (PANSS) Total Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 414)-9.98 ± 14.66
Month 24 (N= 267)-12.52 ± 15.70
SecondaryMean Change From Baseline in PANSS Positive Subscale Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Positive Subscale Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 414)-2.57 ± 4.96
Month 24 (N= 267)-2.91 ± 5.13
SecondaryMean Change From Baseline in PANSS Negative Subscale Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Negative Subscale Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 414)-2.79 ± 4.17
Month 24 (N= 267)-3.48 ± 4.63
SecondaryMean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 414)-0.66 ± 0.96
Month 24 (N= 267)-0.77 ± 1.04
SecondaryMean Change in Clinical Global Impression-Improvement (CGI-I) Score

The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change in Clinical Global Impression-Improvement (CGI-I) Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 408)2.62 ± 1.16
Month 24 (N= 263)2.38 ± 1.15
SecondaryMean Change From Baseline in Young Mania Rating Scale (YMRS) Score

The YMRS consists of 11 items assessing the core symptoms of mania and was used to assess participants with bipolar I disorder, manic and mixed episodes with or without psychotic features: elevated mood, increased motor activity - energy, sexual interest, sleep, irritability, speech (rate and amount), language - thought disorder, content, disruptive - aggressive behavior, appearance, and insight. Each item had 5 or 9 grades of severity, with lower scores indicating milder symptoms. The number of raters within each trial center was to be kept to a minimum. The YMRS Total Score (range 0 to 44) is the sum of the rating scores for 11 items for assessing the core symptoms of mania. A missing value for any YMRS assessment item(s) could have resulted in a missing YMRS Total Score. A higher YMRS Total Score represents greater severity. In this study, 94 participants had bipolar disorder, this explains the N=94 in the table below and these were de novo participants.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Young Mania Rating Scale (YMRS) Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 93)-9.71 ± 10.23
Month 24 (N= 93)-10.02 ± 10.21
SecondaryMean Change From Baseline in Clinical Global Impression Scale - Bipolar (CGI-BP) Version Severity Score

The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Data for 94 de novo participants were available with bipolar disorder.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression Scale - Bipolar (CGI-BP) Version Severity Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 93)-1.26 ± 1.33
Month 24 (N= 93)-1.30 ± 1.37
SecondaryMean Change From Baseline in Clinical Global Impression Scale - Bipolar Version Improvement Score

The CGI-BP scale refers to the global impression of the subject with respect to bipolar disorder. The scale rated the subject's Severity of Illness (CGI-BP-Severity: mania, depression, and overall bipolar illness) and Change From Preceding Phase (CGI-BP-Improvement: mania, depression, and overall bipolar illness) based on a 7- or 8-point scale. Severity of Illness (CGI-BP-Severity) was rated at all visits. At each visit other than Day 0 (Baseline), the Change From Preceding Phase (CGI-BP-Improvement) was judged with respect to participant's condition at Baseline. The CGI-BP Severity Scores (range 1 to 7), as well as CGI-BP Improvement Scores (range 1 to 7) are single-item rating scores, with higher scores representing greater severity or less improvement. Only 94 participants had data at Baseline to explain the N=94 in the table below and these were de novo participants.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression Scale - Bipolar Version Improvement Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 93)2.27 ± 1.28
Month 24 (N= 93)2.17 ± 1.27
SecondaryMean Change From Baseline in General Behavior Inventory (GBI) Scale Total Score for Mania and Depression in Both Parent/Guardian and Subject Version of the Scale

The GBI is a self-report inventory with 73 items focusing on mood-related behaviors, including depressive, hypomanic, and biphasic symptoms. For this trial, two 20-item subscales were utilized: one was completed by the parent/guardian or legal representative, as applicable for local laws, and the other was completed by the participant. Responses were given on a 4-point Likert scale, with 0 being never or hardly ever and 3 being very often or almost constantly. The GBI Total Score for mania (range 0 to 30) is the sum of scores for items 1 to 10 and the GBI Total Score for depression (range 0 to 30) is the sum of scores for items 11 to 20 in the GBI Parent/Guardian or Subject Version panel. Scores from the Parent/Guardian and participant Versions were summarized separately. A missing value for any GBI assessment items could have resulted in a missing GBI Total Score. High scores represent greater psychopathology. Data was only available for 80 de novo participants with bipolar disorder.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in General Behavior Inventory (GBI) Scale Total Score for Mania and Depression in Both Parent/Guardian and Subject Version of the Scale
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 78)-1.62 ± 7.20
Month 24 (N= 78)-1.82 ± 7.37
SecondaryMean Change From Baseline in the Attention Deficit Hyperactive Disorders Rating (ADHD-RS-IV) Scale Score

The ADHD-RS-IV is a reliable and easy-to-administer instrument both for diagnosing ADHD in children and adolescents and for assessing treatment response. Containing 18 items, the scale was linked directly to DSM-IV-TR diagnostic criteria for ADHD. There were 3 versions of the scale: a parent questionnaire on home behaviors (English), a parent questionnaire on home behaviors (Spanish), and a teacher questionnaire on classroom behaviors. For this trial, the parent questionnaire on home behaviors (English) was utilized. The ADHD-RS-IV Total Score (range 0 to 54) is the sum of rating scores for 18 items, with higher scores representing greater severity. A missing value for any ADHD-RS-IV assessment items could have resulted in a missing ADHD-RS-IV Total Score. Data were only available for 82 participants with bipolar disorder and these were de novo participants.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in the Attention Deficit Hyperactive Disorders Rating (ADHD-RS-IV) Scale Score
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 81)-3.25 ± 10.43
Month 24 (N= 81)-2.53 ± 10.73
SecondaryMean Change From Baseline in Children's Global Assessment Scale (CGAS) in Bipolar (de Novo Participants)

The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6 to 17. It was adapted from the Adults Global Assessment Scale. The Global Assessment Scale was a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS Score (range 1 to 100) is a single-item score for rating a child's general level of functioning on a health-illness continuum, with higher scores representing better functioning.

Time frame:
Baseline to Month 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Children's Global Assessment Scale (CGAS) in Bipolar (de Novo Participants)
Units on a scaleOpen-label Treatment Phase
Month 12 (N= 93)14.17 ± 16.01
Month 24 (N= 93)14.00 ± 16.23

Adverse events

Collected over Adverse events were reported from the signing of the informed consent, during the 24-month treatment period until the follow-up visit 30 (± 3) days after the end of trial.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Conversion Phase—2/297 (0.7%)40/297 (13.5%)
Open-label Treatment Phase—49/510 (9.6%)194/510 (38%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventConversion PhaseOpen-label Treatment Phase
SchizophreniaPsychiatric disorders0/29718/510
Suicidal ideationPsychiatric disorders0/2978/510
Bipolar disorderPsychiatric disorders0/2977/510
AggressionPsychiatric disorders0/2973/510
AgitationPsychiatric disorders0/2973/510
Hallucination, auditoryPsychiatric disorders0/2972/510
Suicide attemptPsychiatric disorders0/2972/510
Bipolar I disorderPsychiatric disorders1/2971/510
Tooth disorderGastrointestinal disorders1/2970/510
Gilbert's syndromeCongenital, familial and genetic disorders0/2971/510
Most frequent other events
Most frequent other events
EventConversion PhaseOpen-label Treatment Phase
HeadacheNervous system disorders23/29767/510
Weight increasedInvestigations1/29738/510
SomnolenceNervous system disorders20/29733/510
NasopharyngitisInfections and infestations5/29734/510
AnxietyPsychiatric disorders6/29732/510
VomitingGastrointestinal disorders4/29730/510
SchizophreniaPsychiatric disorders1/29730/510

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Study Participants
Mean15.2 ± 1.6
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female316
Male208
08

Study locations

101 sites
  • Study Site
    Dothan, Alabama 36303, United States
  • Study Site
    Downey, California 90241, United States
  • Study Site
    Miami, Florida 33155, United States
  • Study Site
    Miami, Florida 33166, United States
  • Study Site
    Atlanta, Georgia 30308, United States
  • Study Site
    Smyrna, Georgia 30080, United States
  • Study Site
    Oak Brook, Illinois 60523, United States
  • Study Site
    Wichita, Kansas 67214, United States
  • Study Site
    Minneapolis, Minnesota 55454, United States
  • Study Site
    Buffalo, New York 14215, United States
  • Study Site
    Stony Brook, New York 11794, United States
  • Study Site
    Chapel Hill, North Carolina 27517, United States
  • Study Site
    Cincinnati, Ohio 45219, United States
  • Study Site
    Cleveland, Ohio 44106, United States
  • Study Site
    Oklahoma City, Oklahoma 73116, United States
  • Study Site
    Philadelphia, Pennsylvania 19139, United States
  • Study Site
    Houston, Texas 77090, United States
  • Study Site
    San Antonio, Texas 78258, United States
  • Study Site
    The Woodlands, Texas 77381, United States
  • Study Site
    Richmond, Virginia 23230, United States
  • Study Site
    Bellevue, Washington 98004, United States
  • Study Site
    Bothell, Washington 98011, United States
  • Study Site
    Milwaukee, Wisconsin 53227, United States
  • Study Site
    Bourgas, 8000, Bulgaria
  • Study Site
    Pazardjik, 4400, Bulgaria
  • Study Site
    Plovdiv, 4000, Bulgaria
  • Study Site
    Rousse, 7004, Bulgaria
  • Study Site 2
    Sofia, 1431, Bulgaria
  • Study Site
    Targovishte, 7700, Bulgaria
  • Study Site 1
    Varna, 9010, Bulgaria
  • Study Site 2
    Varna, 9010, Bulgaria
  • Study Site
    Rijeka, 51000, Croatia
  • Study Site 1
    Zagreb, 10000, Croatia
  • Study Site 2
    Zagreb, 10000, Croatia
  • Study Site
    Budapest, H-1021, Hungary
  • Study Site
    Budapest, H-1135, Hungary
  • Study Site
    Gyula, H-5700, Hungary
  • Study Site
    Szeged, H-6725, Hungary
  • Study Site
    Vijayawada, Andhra Pradesh 520002, India
  • Study Site
    Visakhapatnam, Andhra Pradesh 530002, India
  • Study Site
    Visakhapatnam, Andhra Pradesh 530017, India
  • Study Site 1
    Ahmedabad, Gujarat 380006, India
  • Study Site 2
    Ahmedabad, Gujarat 380006, India
  • Study Site
    Ahmedabad, Gujarat 380013, India
  • Study Site
    Maninagar, Ahmedabad, Gujarat 380008, India
  • Study Site
    Mangalore, Karnataka 575001, India
  • Study Site
    Calicut, Kerala 673009, India
  • Study Site
    Nasik, Maharashtra 422101, India
  • Study Site
    Ludhiana, Punjab 141001, India
  • Study Site
    Jaipur, Rajasthan 302017, India
  • Study Site
    Chennai, Tamil Nadu 600003, India
  • Study Site
    Maduri, Tamil Nadu 625020, India
  • Study Site
    Kanpur, Uttar Pradesh 208005, India
  • Study Site
    Lucknow, Uttar Pradesh 226003, India
  • Study Site
    Varanasi, Uttar Pradesh 221005, India
  • Study Site
    Guntur, 522001, India
  • Study Site
    Kuala Lumpur, Wilayah Persekutuan 50603, Malaysia
  • Study Site
    Dasmarinas City, Cavite 4114, Philippines
  • Study Site
    Manila City, Metro Manila 1000, Philippines
  • Study Site
    Iloilo City, 5000, Philippines
  • Study Site
    Mandaluyong City, 1553, Philippines
  • Study Site
    Białystok, 15-879, Poland
  • Study Site
    Gdansk Wrzeszcz, 80-282, Poland
  • Study Site
    Toruń, 87-100, Poland
  • Study Site
    Wrocław, 50-227, Poland
  • Study Site
    Wrocław, 54-235, Poland
  • Study Site
    Cluj-Napoca, Cluj 400084, Romania
  • Study Site
    Timisoara, Timis 300239, Romania
  • Study Site
    Bucharest, 041914, Romania
  • Study Site
    Craiova, Dolj, 200620, Romania
  • Study Site
    Iasi, 700282, Romania
  • Study Site
    Ekaterinburg, 620030, Russian Federation
  • Study Site
    Kazan, 420061, Russian Federation
  • Study Site
    Lipetsk, 399313, Russian Federation
  • Study Site
    Moscow, 124617, Russian Federation
  • Study Site
    Moscow, 127083, Russian Federation
  • Study Site
    Nizhniy Novgorod, 603155, Russian Federation
  • Study Site
    Novosibirsk, 630091, Russian Federation
  • Study Site
    Orenburg region, 460551, Russian Federation
  • Study Site
    Petrozavodsk, 185001, Russian Federation
  • Study Site
    Saratov, 410028, Russian Federation
  • Study Site
    St. Petersburg, 190005, Russian Federation
  • Study Site
    St. Petersburg, 197376, Russian Federation
  • Study Site
    Tomsk, 634014, Russian Federation
  • Study Site
    Tonnelnyi Township, 357034, Russian Federation
  • Study Site
    Yaroslavl, 150003, Russian Federation
  • Study Site 1
    Belgrade, 11000, Serbia
  • Study Site 2
    Belgrade, 11000, Serbia
  • Study Site
    Novi Sad, 21000, Serbia
  • Study Site
    Taipei City, 110, Taiwan
  • Study Site
    Dnepropetrovsk, 49005, Ukraine
  • Study Site
    Donetsk, 83037, Ukraine
  • Study Site 1
    Kharkiv, 61068, Ukraine
  • Study Site 2
    Kharkiv, 61068, Ukraine
  • Study Site
    Kherson, 73488, Ukraine
  • Study Site
    Lugansk, 91045, Ukraine
  • Study Site
    Lviv, 79021, Ukraine
  • Study Site
    Odessa, 65006, Ukraine
  • Study Site
    Simferopol Crimea, 95006, Ukraine
  • Study Site
    Temopil, 4620, Ukraine

Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Aug 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2010
First posted
May 13, 2010
Start
Jul 2010
Primary completionActual
Aug 2014
CompletionActual
Sep 2014
Results first posted
Feb 8, 2016
Last update
Feb 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01122927
Responsible party
Sponsor
First posted
May 13, 2010
Start date
Jul 2010
Primary completion
Aug 2014
Completion
Sep 2014
Results posted
Feb 8, 2016
Last update
Feb 8, 2016

Study contacts

Eva Kohegyi, MD
study director · Otsuka Pharmaceutical Development and Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion